AUROBINDO

August 5, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/Madam,

Sub: Completion of US FDA Inspection at our Unit VII – Reg.,
Ref: Our Letters dated October 7 & 11, 2019, January 30, 2020 and May 10, 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letters, this is to inform you that:

The Company's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an **Establishment Inspection Report** (EIR) mentioning the inspection a **Voluntary Action Initiated** (VAI) from the US FDA and with this inspection is concluded.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary